Humanigen Inc (HGENQ)

[cowtown jay]

"Note: I think I need to look more closely at Acute GvHD. This could be the dark horse winner of lenzilumab's first authorization or approval. Partnership interest. TeraImmune TReg work. Phase 2/3 trial."

It does indeed look like there could be reason to hope for good news regarding the use of lenz in the prevention and treatment of Acute Graft Versus Host Disease.

"Humanigen Announces Clinical Trial Collaboration to
Evaluate Lenzilumab in Acute Graft Versus Host Disease

11/11/2021

Humanigen is supporting the University of Birmingham to conduct a Phase 2/3, potentially registrational, clinical trial at IMPACT stem cell transplant centers across the United Kingdom
The “Risk Adapted Therapy in Acute GvHD”, or “RATinG”, study is expected to begin enrolling in 1H22"

https://s28.q4cdn.com/539885110/files/doc_news/Humanigen-Announces-Clinical-Trial-Collaboration-to-Evaluate-Lenzilumab-in-Acute-Graft-Versus-Host-Disease-2021.pdf

Humanigen will also advance its plan to study lenzilumab in acute graft versus host disease ("aGvHD") that occurs in patients undergoing bone marrow transplant, which will be the focus of the RATinG study that is expected to enroll its first patient in 3Q22.

https://www.newsfilecorp.com/release/131903/Humanigen-Implements-Strategic-Realignment-of-Pipeline-and-Resources-to-Achieve-Key-Clinical-Milestones

"Continuing to execute the RATinG study for lenzilumab for the early treatment of aGvHD with the goal of reporting a planned interim assessment of the first 20 patients in 2Q23"

https://www.newsfilecorp.com/release/131903/Humanigen-Implements-Strategic-Realignment-of-Pipeline-and-Resources-to-Achieve-Key-Clinical-Milestones

See also the corporate preentation (thru pg 15)

https://ir.humanigen.com/English/events-and-presentations/default.aspx

This could also explain why Humanigen is keen on partnering/combining with PCI, for their services in the UK.

https://pci.com/humanigen-preparations-for-commercialization/

In addition, it appears that the company is moving forward partnering/combining with Baudax/TeraImmune.

"TeraImmune develops cell therapeutics for autoimmune diseases and immune-related disorders. It uses regulatory T (Treg) cells from a donor and makes cells for hemophilia, multiple sclerosis, and graft-versus-host disease from stem cell transplantation, enabling the healthcare industry to suppress unwanted immune reactions without side effects in patients with autoimmune diseases. The company was founded in 2016 and is based in Germantown, Maryland. In June 2023, TeraImmune was acquired by Baudax Bio. The terms of the transactions were not disclosed."

https://www.cbinsights.com/company/teraimmune

Also, this indication could relate to our latest patent

"Method of increasing the efficacy of CAR-T immunotherapy using lenzilumab
Patent number: 11673962
Abstract: Methods of inhibiting or reducing the incidence or the severity of immunotherapy-related toxicity in a subject, the method comprising a step of administering a recombinant hGMCSF antagonist to the subject, wherein said administering inhibits or reduces the incidence or the severity of immunotherapy-related toxicity in said subject, are provided. An hGMCSF antagonist for use in methods of inhibiting or reducing the incidence or the severity of immunotherapy-related toxicity in a subject also are provided.
Type: Grant
Filed: October 2, 2018
Date of Patent: June 13, 2023
Assignee: HUMANIGEN, INC.
Inventors: Cameron Durrant, Dale Chappell"

Notice the 2018 file date, well before covid.

https://patents.justia.com/assignee/humanigen-inc